Using nasal povidone-iodine to prevent bloodstream infections and transmission of Staphylococcus aureus among haemodialysis patients: a stepped-wedge cluster randomised control trial protocol

Ana-Monica Racila, Amy M J O'Shea, Rajeshwari Nair, Kimberly Dukes, Loreen A Herwaldt, Linda Boyken, Daniel Diekema, Melissa A Ward, Jason Cobb, Jesse Jacob, David Pegues, Susan Bleasdale, Anitha Vijayan, Anubha Mutneja, Mony Fraer, Debra O'Connell-Moore, Pam Tolomeo, Minerva Mendez, Erin Jaworski, Marin L Schweizer, Ana-Monica Racila, Amy M J O'Shea, Rajeshwari Nair, Kimberly Dukes, Loreen A Herwaldt, Linda Boyken, Daniel Diekema, Melissa A Ward, Jason Cobb, Jesse Jacob, David Pegues, Susan Bleasdale, Anitha Vijayan, Anubha Mutneja, Mony Fraer, Debra O'Connell-Moore, Pam Tolomeo, Minerva Mendez, Erin Jaworski, Marin L Schweizer

Abstract

Introduction: Approximately 38% of haemodialysis patients carry Staphylococcus aureus in their noses, and carriers have a nearly four-fold increased risk of S. aureus access-related bloodstream infections (BSIs) compared with non-carriers. Our objective is to determine the clinical efficacy and effectiveness of a novel intervention using nasal povidone-iodine (PVI) to prevent BSIs among patients in haemodialysis units. We will survey patients and conduct qualitative interviews with healthcare workers to identify barriers and facilitators to implementing the intervention.

Methods and analysis: We will perform an open-label, stepped-wedge cluster randomised trial to assess the effectiveness of nasal PVI compared with standard care. Sixteen outpatient haemodialysis units will participate in the study. The 3-year trial period will be divided into a 4-month baseline period and eight additional 4-month time blocks. The primary outcome of the study will be S. aureus BSI, defined as a S. aureus positive blood culture collected in the outpatient setting or within one calendar day after a hospital admission. The study team will evaluate characteristics of individual patients and the clusters by exposure status (control or intervention) to assess the balance between groups, and calculate descriptive statistics such as average responses separately for control and intervention survey questions.

Ethics and dissemination: This study has received IRB approval from all study sites. A Data Safety and Monitoring Board will monitor this multicentre clinical trial. We will present our results at international meetings. The study team will publish findings in peer-reviewed journals and make each accepted peer-reviewed manuscript publicly available.

Trial registration number: NCT04210505.

Keywords: dialysis; infection control; nephrology; qualitative research.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. United States Renal Data System . USRDS annual data report: epidemiology of kidney disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (US), 2020.
    1. Dalrymple LS, Mu Y, Romano PS, et al. . Outcomes of infection-related hospitalization in Medicare beneficiaries receiving in-center hemodialysis. Am J Kidney Dis 2015;65:754–62. 10.1053/j.ajkd.2014.11.030
    1. Patel PR, Kallen AJ, Arduino MJ. Epidemiology, surveillance, and prevention of bloodstream infections in hemodialysis patients. Am J Kidney Dis 2010;56:566–77. 10.1053/j.ajkd.2010.02.352
    1. Nguyen DB, Shugart A, Lines C, et al. . National healthcare safety network (NHSN) dialysis event surveillance report for 2014. Clin J Am Soc Nephrol 2017;12:1139–46. 10.2215/CJN.11411116
    1. Landry DL, Braden GL, Gobeille SL, et al. . Emergence of gentamicin-resistant bacteremia in hemodialysis patients receiving gentamicin lock catheter prophylaxis. Clin J Am Soc Nephrol 2010;5:1799–804. 10.2215/CJN.01270210
    1. Maki DG, Ash SR, Winger RK, et al. . A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multi-center, controlled, randomized trial. Crit Care Med 2011;39:613–20. 10.1097/CCM.0b013e318206b5a2
    1. Engemann JJ, Friedman JY, Reed SD, et al. . Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. Infect Control Hosp Epidemiol 2005;26:534–9. 10.1086/502580
    1. Nissenson AR, Dylan ML, Griffiths RI, et al. . Clinical and economic outcomes of Staphylococcus aureus septicemia in ESRD patients receiving hemodialysis. Am J Kidney Dis 2005;46:301–8. 10.1053/j.ajkd.2005.04.019
    1. Li Y, Friedman JY, O'Neal BF, et al. . Outcomes of Staphylococcus aureus infection in hemodialysis-dependent patients. Clin J Am Soc Nephrol 2009;4:428–34. 10.2215/CJN.03760708
    1. Saxena AK, Panhotra BR, Venkateshappa CK, et al. . The impact of nasal carriage of methicillin-resistant and methicillin-susceptible Staphylococcus a ureus (MRSA & MSSA) on vascular access-related septicemia among patients with type-II diabetes on dialysis. Ren Fail 2002;24:763–77. 10.1081/JDI-120015679
    1. Vaziri ND, Pahl MV, Crum A, et al. . Effect of uremia on structure and function of immune system. J Ren Nutr 2012;22:149–56. 10.1053/j.jrn.2011.10.020
    1. Nguyen DB, Lessa FC, Belflower R, et al. . Invasive methicillin-resistant Staphylococcus aureus infections among patients on chronic dialysis in the United States, 2005-2011. Clin Infect Dis 2013;57:1393–400. 10.1093/cid/cit546
    1. Boelaert JR, Van Landuyt HW, Godard CA, et al. . Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemias in haemodialysis patients. Nephrol Dial Transplant 1993;8:235–9.
    1. Schmid H, Romanos A, Schiffl H, et al. . Persistent nasal methicillin-resistant Staphylococcus aureus carriage in hemodialysis outpatients: a predictor of worse outcome. BMC Nephrol 2013;14:93. 10.1186/1471-2369-14-93
    1. Yu VL, Goetz A, Wagener M, et al. . Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med 1986;315:91–6. 10.1056/NEJM198607103150204
    1. Boelaert JR, Van Landuyt HW, Gordts BZ, et al. . Nasal and cutaneous carriage of Staphylococcus aureus in hemodialysis patients: the effect of nasal mupirocin. Infect Control Hosp Epidemiol 1996;17:809–11. 10.2307/30141175
    1. Grothe C, Taminato M, Belasco A, et al. . Prophylactic treatment of chronic renal disease in patients undergoing peritoneal dialysis and colonized by Staphylococcus aureus: a systematic review and meta-analysis. BMC Nephrol 2016;17:115. 10.1186/s12882-016-0329-0
    1. Dalrymple LS, Johansen KL, Chertow GM, et al. . Infection-Related hospitalizations in older patients with ESRD. Am J Kidney Dis 2010;56:522–30. 10.1053/j.ajkd.2010.04.016
    1. Nair R, Perencevich EN, Blevins AE, et al. . Clinical Effectiveness of Mupirocin for Preventing Staphylococcus aureus Infections in Nonsurgical Settings: A Meta-analysis. Clin Infect Dis 2016;62:618–30. 10.1093/cid/civ901
    1. Pérez-Fontán M, Rosales M, Rodríguez-Carmona A, et al. . Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002;39:337–41. 10.1053/ajkd.2002.30553
    1. Tacconelli E, Carmeli Y, Aizer A, et al. . Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis. Clin Infect Dis 2003;37:1629–38. 10.1086/379715
    1. Kluytmans JA, Manders MJ, van Bommel E, et al. . Elimination of nasal carriage of Staphylococcus aureus in hemodialysis patients. Infect Control Hosp Epidemiol 1996;17:793–7. 10.1086/647238
    1. Kunisada T, Yamada K, Oda S, et al. . Investigation on the efficacy of povidone-iodine against antiseptic-resistant species. Dermatology 1997;195 Suppl 2:14–18. 10.1159/000246025
    1. Barry AL, Fuchs PC, Brown SD. Lack of effect of antibiotic resistance on susceptibility of microorganisms to chlorhexidine gluconate or povidone iodine. Eur J Clin Microbiol Infect Dis 1999;18:920–1. 10.1007/s100960050434
    1. Food and Drug Administration, HHS. . Safety and effectiveness of health care antiseptics; topical antimicrobial drug products for over-the-counter human use. final rule. Fed Regist 2017;82:60474.
    1. Hemming K, Haines TP, Chilton PJ, et al. . The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting. BMJ 2015;350:h391. 10.1136/bmj.h391
    1. Hussey MA, Hughes JP. Design and analysis of stepped wedge cluster randomized trials. Contemp Clin Trials 2007;28:182–91. 10.1016/j.cct.2006.05.007
    1. Weiner LM, Webb AK, Limbago B, et al. . Antimicrobial-Resistant pathogens associated with healthcare-associated infections: summary of data reported to the National healthcare safety network at the centers for disease control and prevention, 2011–2014. Infection Control & Hospital Epidemiology 2016;37:1288–301. 10.1017/ice.2016.174
    1. Lanker Klossner B, Widmer H-R, Frey F. Nondevelopment of resistance by bacteria during Hospital use of Povidone-lodine. Dermatology 1997;195:10–13. 10.1159/000246024
    1. Gocke DJ, Ponticas S, Pollack W. In vitro studies of the killing of clinical isolates by povidone-iodine solutions. J Hosp Infect 1985;6 Suppl A:59–66. 10.1016/S0195-6701(85)80047-5
    1. Anderson MJ, David ML, Scholz M, et al. . Efficacy of skin and nasal povidone-iodine preparation against mupirocin-resistant methicillin-resistant Staphylococcus aureus and S. aureus within the anterior nares. Antimicrob Agents Chemother 2015;59:2765–73. 10.1128/AAC.04624-14
    1. Torres EG, Lindmair-Snell JM, Langan JW, et al. . Is Preoperative Nasal Povidone-Iodine as Efficient and Cost-Effective as Standard Methicillin-Resistant Staphylococcus aureus Screening Protocol in Total Joint Arthroplasty? J Arthroplasty 2016;31:215–8. 10.1016/j.arth.2015.09.030
    1. Maslow J, Hutzler L, Cuff G, et al. . Patient experience with mupirocin or povidone-iodine nasal decolonization. Orthopedics 2014;37:e576–81. 10.3928/01477447-20140528-59
    1. Phillips M, Rosenberg A, Shopsin B, et al. . Preventing surgical site infections: a randomized, open-label trial of nasal mupirocin ointment and nasal povidone-iodine solution. Infect Control Hosp Epidemiol 2014;35:826–32. 10.1086/676872
    1. Bebko SP, Green DM, Awad SS. Effect of a preoperative decontamination protocol on surgical site infections in patients undergoing elective orthopedic surgery with hardware implantation. JAMA Surg 2015;150:390. 10.1001/jamasurg.2014.3480
    1. Fong IW. Prevention of haemodialysis and peritoneal dialysis catheter related infection by topical povidone-iodine. Postgrad Med J 1993;69 Suppl 3:515–7.
    1. Al-Said J, Pagaduan AC. Infection-free hemodialysis: can it be achieved? Saudi J Kidney Dis Transpl 2009;20:677.
    1. Liyanage T, Ninomiya T, Jha V, et al. . Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 2015;385:385. 10.1016/S0140-6736(14)61601-9

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit